Garth T Whiteside

List of Publications by Year
in descending order

52 papers	3,196 citations	186209 28 h-index	182361 51 g-index
52 all docs	52 docs citations	52 times ranked	4120 citing authors

#	Article	IF	Citations
1	Current and potential pharmacological treatment options for insomnia in patients with alcohol use disorder in recovery. Neuropsychopharmacology Reports, 2020, 40, 211-223.	1.1	9
2	Measuring and realizing the translational significance of preclinical inÂvivo studies of painful osteoarthritis. Osteoarthritis and Cartilage, 2017, 25, 376-384.	0.6	9
3	Pharmacological evaluation of NSAID-induced gastropathy as a â€œTranslatableâ€•model of referred visceral sensitivity. World Journal of Gastroenterology, 2017, 23, 6065-6076.	1.4	1
4	Ensuring transparency and minimization of methodologic bias in preclinical pain research. Pain, 2016, 157, 901-909.	2.0	70
5	A randomized, double-blind, positive-controlled, 3-way cross-over human experimental pain study of a TRPV1 antagonist (V116517) in healthy volunteers and comparison with preclinical profile. Pain, 2016, 157, 2057-2067.	2.0	29
6	Robustness of arterial blood gas analysis for assessment of respiratory safety pharmacology in rats. Journal of Pharmacological and Toxicological Methods, 2016, 78, 32-41.	0.3	5
7	Preclinical Pharmacological Approaches in Drug Discovery for Chronic Pain. Advances in Pharmacology, 2016, 75, 303-323.	1.2	8
8	An industry perspective on the role and utility of animal models of pain in drug discovery. Neuroscience Letters, 2013, 557, 65-72.	1.0	49
9	Negative allosteric modulation of metabotropic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression. Neuropharmacology, 2013, 66, 202-214.	2.0	71
10	A Review of the NOP (ORL-1)-Nociceptin/Orphanin FQ System Covering Receptor Structure, Distribution, Role in Analgesia and Reward and Interactions with Other Receptors. ACS Symposium Series, 2013, , 327-368.	0.5	6
11	Discovery of Novel Selective Norepinephrine Inhibitors: 1-(2-Morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-Dioxides (WYE-114152). Journal of Medicinal Chemistry, 2011, 54, 6824-6831.	2.9	8
12	Inflammatory Cytokine and Chemokine Expression Is Differentially Modulated Acutely in the Dorsal Root Ganglion in Response to Different Nerve Root Compressions. Spine, 2011, 36, 197-202.	1.0	13
13	Dynamic Changes in the MicroRNA Expression Profile Reveal Multiple Regulatory Mechanisms in the Spinal Nerve Ligation Model of Neuropathic Pain. PLoS ONE, 2011, 6, e17670.	1.1	123
14	Inhibition of osteoclasts prevents cartilage loss and pain in a rat model of degenerative joint disease. Osteoarthritis and Cartilage, 2010, 18, 1319-1328.	0.6	110
15	Depression-like phenotype following chronic CB1 receptor antagonism. Neurobiology of Disease, 2010, 39, 148-155.	2.1	142
16	Tri-partite complex for axonal transport drug delivery achieves pharmacological effect. BMC Neuroscience, 2010, 11, 8.	0.8	13
17	Purinergic receptor-mediated morphological changes in microglia are transient and independent from inflammatory cytokine release. European Journal of Pharmacology, 2010, 643, 202-210.	1.7	18
18	Structureâ€“activity relationships of norepinephrine reuptake inhibitors with benzothiadiazine dioxide or dihydrosulfostyril cores. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 1555-1558.	1.0	8

#	Article	IF	Citations
19	WAYâ€318068: a novel, potent and selective noradrenaline reâ€uptake inhibitor with activity in rodent models of pain and depression. British Journal of Pharmacology, 2010, 160, 1105-1118.	2.7	10
20	Genetic and Functional Analysis of Human P2X5 Reveals a Distinct Pattern of Exon 10 Polymorphism with Predominant Expression of the Nonfunctional Receptor Isoform. Molecular Pharmacology, 2010, 77, 953-960.	1.0	28
21	Loss of Retrograde Endocannabinoid Signaling and Reduced Adult Neurogenesis in Diacylglycerol Lipase Knock-out Mice. Journal of Neuroscience, 2010, 30, 2017-2024.	1.7	404
22	Monoacylglycerol Lipase Activity Is a Critical Modulator of the Tone and Integrity of the Endocannabinoid System. Molecular Pharmacology, 2010, 78, 996-1003.	1.0	205
23	Discovery of Novel Selective Norepinephrine Reuptake Inhibitors: 4-[3-Aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231). Journal of Medicinal Chemistry, 2010, 53, 4511-4521.	2.9	15
24	Pain is a salient â€œstressorâ€•that is mediated by corticotropin-releasing factor-1 receptors. Neuropharmacology, 2010, 59, 160-166.	2.0	39
25	1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as Potent and Selective Norepinephrine Reuptake Inhibitors. Journal of Medicinal Chemistry, 2010, 53, 2051-2062.	2.9	22
26	Abnormal gait, due to inflammation but not nerve injury, reflects enhanced nociception in preclinical pain models. Brain Research, 2009, 1295, 89-98.	1.1	57
27	Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Brain Research Reviews, 2009, 60, 255-266.	9.1	180
28	Age-dependent effects of the cannabinoid CB1 antagonist SR141716A on food intake, body weight change, and pruritus in rats. Psychopharmacology, 2009, 206, 155-165.	1.5	12
29	CNS penetration of small molecules following local inflammation, widespread systemic inflammation or direct injury to the nervous system. Life Sciences, 2009, 85, 450-456.	2.0	26
30	1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: Potent, Selective, and Orally Efficacious Norepinephrine Reuptake Inhibitors. Journal of Medicinal Chemistry, 2009, 52, 5703-5711.	2.9	23
31	Estrogen Receptor Neurobiology and its Potential for Translation into Broad Spectrum Therapeutics for CNS Disorders. Current Molecular Pharmacology, 2009, 2, 215-236.	0.7	52
32	Predictive validity of animal pain models? A comparison of the pharmacokineticâ€“pharmacodynamic relationship for pain drugs in rats and humans. Neuropharmacology, 2008, 54, 767-775.	2.0	120
33	Anatomical localization and expression pattern for the NMDA-2D receptor subunit in a rat model of neuropathic pain. Neuroscience, 2008, 155, 492-502.	1.1	13
34	The persistence of a long-term negative affective state following the induction of either acute or chronic pain. Pain, 2008, 140, 436-445.	2.0	73
35	Advances in the development of novel analgesics. Expert Opinion on Therapeutic Patents, 2008, 18, 1027-1067.	2.4	9
36	Successful use of axonal transport for drug delivery by synthetic molecular vehicles. Nature Precedings, 2008, , .	0.1	0

#	Article	IF	Citations
37	The Role of the Cannabinoid CB2 Receptor in Pain Transmission and Therapeutic Potential of Small Molecule CB2 Receptor Agonists. Current Medicinal Chemistry, 2007, 14, 917-936.	1.2	125
38	Pharmacological Characterization of the Muscarinic Agonist (3R,4R)-3-(3-Hexylsulfanyl-pyrazin-2-yloxy)-1-aza-bicyclo[2.2.1]heptane (WAY-132983) in in Vitro and in Vivo Models of Chronic Pain. Journal of Pharmacology and Experimental Therapeutics, 2007, 322, 1294-1304.	1.3	35
39	Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers. British Journal of Pharmacology, 2007, 151, 1061-1070.	2.7	78
40	Neuropathy-induced osteopenia in rats is not due to a reduction in weight born on the affected limb. Bone, 2006, 38, 387-393.	1.4	23
41	Pharmacology of 2-[4-(4-Chloro-2-fluorophenoxy)phenyl]-pyrimidine-4-carboxamide: A Potent, Broad-Spectrum State-Dependent Sodium Channel Blocker for Treating Pain States. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 1083-1093.	1.3	35
42	A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833. European Journal of Pharmacology, 2005, 528, 65-72.	1.7	87
43	The Role of Central and Peripheral Î¼ Opioid Receptors in Inflammatory Pain and Edema: A Study Using Morphine and DiPOA ([8-(3,3-Diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triaza-spiro[4.5]dec-3-yl]-acetic Acid). Journal of Pharmacology and Experimental Therapeutics, 2005, 314, 1234-1240.	1.3	36
44	Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology, 2005, 48, 658-672.	2.0	256
45	DiPOA ([8-(3,3-Diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic Acid), a Novel, Systemically Available, and Peripherally Restricted Mu Opioid Agonist with Antihyperalgesic Activity: II. In Vivo Pharmacological Characterization in the Rat. Journal of Pharmacology and Experimental Therapeutics, 2004, 310, 793-799.	1.3	20
46	Pharmacological characterisation of a rat model of incisional pain. British Journal of Pharmacology, 2004, 141, 85-91.	2.7	141
47	A-317491, a selective P2X3/P2X2/3 receptor antagonist, reverses inflammatory mechanical hyperalgesia through action at peripheral receptors in rats. European Journal of Pharmacology, 2004, 504, 45-53.	1.7	74
48	Modifications to the hand-held Gene Gun: improvements for in vitro Biolistic transfection of organotypic neuronal tissue. Journal of Neuroscience Methods, 2001, 112, 57-64.	1.3	82
49	Cell death in the superficial dorsal horn in a model of neuropathic pain. Journal of Neuroscience Research, 2001, 64, 168-173.	1.3	126
50	Effect of colchicine on neuropeptide Y expression in rat dorsal root ganglia and spinal cord. Neuroscience Letters, 1999, 259, 45-48.	1.0	10
51	Differential time course of neuronal and glial apoptosis in neonatal rat dorsal root ganglia after sciatic nerve axotomy. European Journal of Neuroscience, 1998, 10, 3400-3408.	1.2	40
52	An improved method for detection of apoptosis in tissue sections and cell culture, using the TUNEL technique combined with Hoechst stain. Brain Research Protocols, 1998, 2, 160-164.	1.7	48